US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SPCX $158.96 ▲+0.00% SDEV $7.48 ▲+0.00% TSLA $370.59 ▲+0.00% AMD $633.91 ▲+0.00%
FinancialContent

Articles published by OKYO Pharma LTD

< Previous 1 2 3 Next >
News headline image
OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
News headline image
OKYO Pharma to Ring the Opening Bell at Nasdaq
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
News headline image
OKYO Pharma Announces Chairman and Founder Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
News headline image
OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
News headline image
OKYO Pharma Announces Chairman and Founder Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
News headline image
OKYO Pharma Announces Chairman and Founder Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
News headline image
OKYO Pharma to Present at OIS XV in San Diego
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
News headline image
OKYO Pharma to Present at BIO-Europe 2025 in Vienna
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
News headline image
OKYO Pharma Announces Chairman and Founder Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
News headline image
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
News headline image
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
News headline image
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
News headline image
OKYO Pharma to Present at the Bio International Convention
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
News headline image
OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
News headline image
FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
News headline image
OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
News headline image
OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
News headline image
OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
News headline image
OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
News headline image
OKYO Pharma Announces Chairman and CEO Acquire Shares
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
News headline image
OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
News headline image
OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
News headline image
OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
News headline image
OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
News headline image
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
News headline image
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
News headline image
OKYO Pharma Announces Chairman Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
News headline image
OKYO Pharma Announces Chairman Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
News headline image
OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
News headline image
OKYO Pharma CEO Interview to Air on Bloomberg TV
From OKYO Pharma LTD
Via GlobeNewswire
Tickers OKYO
< Previous 1 2 3 Next >